生物谷(833266) - 2022 Q4 - 年度业绩

Financial Performance - The company reported a total operating revenue of ¥587,519,585.12, representing a year-on-year increase of 3.77%[4] - The net profit attributable to shareholders was estimated at -¥47,642,140.67, a decline of 157.07% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was projected at -¥79,131,166.88, down 268.11% year-on-year[5] - Basic earnings per share were expected to be -¥0.38, a decrease of 156.72% from the previous year[5] Assets and Equity - Total assets at the end of the reporting period were estimated at ¥1,240,309,977.63, a decrease of 4.50% year-on-year[5] - Shareholders' equity attributable to the company was projected to be ¥1,012,917,645.77, down 4.95% compared to the previous year[5] - The estimated net asset value per share was ¥7.91, reflecting a decline of 5.04% year-on-year[5] Expenses and Challenges - Increased sales expenses were attributed to efforts to stabilize revenue amidst market challenges, including the impact of the pandemic and policy changes[6] - The decline in profit was also influenced by the failure of the controlling shareholder to repay funds on time, leading to an estimated profit reduction of approximately ¥89.95 million[7] Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[8]